MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

Author(s):

Panelists discuss the importance of minimal residual disease negativity as a primary outcome measure and the treatment strategies for patients who are eligible for transplantation but choose to decline it, including preferred induction regimens for this population.

EP: 1.Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

EP: 2.Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

EP: 3.Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

Now Viewing

EP: 4.MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

EP: 5.Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma

EP: 6.Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

EP: 7.Considerations for Use of CAR T-cell Therapy in Multiple Myeloma

EP: 8.CAR T-cell Therapies for Multiple Myeloma: KarMMa-3 and CARTITUDE-4 Study Updates at IMS 2024

EP: 9.Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers

EP: 10.Importance of Early Referral for CAR T-cell Therapy in Multiple Myeloma and Patient Quality of Life

Dr Ajai Chari to Dr Raje: What are your thoughts on minimal residual disease negativity as a primary outcome?
Dr Ajai Chari to Dr Rossi: For patients who are eligible for transplantation but decline, what is your treatment approach for this patient population? Do you have a preferred induction regimen?